CoChat

Targeting Kv7 Potassium Channels for Epilepsy

Open access

The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.

Abstract

Voltage-gated Kv7 potassium channels, particularly Kv7.2 and Kv.7.3 channels, play a critical role in modulating susceptibility to seizures, and mutations in genes that encode these channels cause heterogeneous epilepsy phenotypes. On the basis of this evidence, activation of Kv7.2 and Kv.7.3 channels has long been considered an attractive target in the search for novel antiseizure medications. Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae. A novel formulation of ezogabine for pediatric use (XEN496) has been recently investigated in children with KCNQ2-related developmental and epileptic encephalopathy, but the trial was terminated prematurely for reasons unrelated to safety. Among novel Kv7.2/3 openers in clinical development, azetukalner has shown dose-dependent efficacy against drug-resistant focal seizures with a good tolerability profile and no evidence of pigmentation-related adverse effects in early clinical studies, and it is now under investigation in phase III trials for the treatment of focal seizures, generalized tonic-clonic seizures, and major depressive disorder. Another Kv7.2/3 activator, BHV-7000, has completed phase I studies in healthy subjects, with excellent tolerability at plasma drug concentrations that exceed the median effective concentrations in a preclinical model of anticonvulsant activity, but no efficacy data in patients with epilepsy are available to date. Among other Kv7.2/3 activators in clinical development as potential antiseizure medications, pynegabine and CB-003 have completed phase I safety and pharmacokinetic studies, but results have not been yet reported. Overall, interest in targeting Kv7 channels for the treatment of epilepsy and for other indications remains strong. Future breakthroughs in this area could come from exploitation of mechanistic differences in the action of Kv7 activators, and from the development of molecules that combine Kv7 activation with other mechanisms of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-024-01155-3

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Hypothetical mechanism of activation of Kv7 channels by ezogabine. Only two of the four subunits forming the functional channel are shown for simplicity. (A) Under resting conditions, the S4 segment of the voltage-sensing domain (VSD) is positioned toward the intracellular side of the membrane. This configuration is stabilized by calmodulin bridging the core region at the S2–S3 linker [where phosphatidylinositol-4,5-biphosphate (PIP2) also binds] and the C-terminus at two α-helical regions denominated HA and HB. The inner pore gate (IG) is closed, the central cavity (CC) above the IG and below the selectivity filter (SF), is narrow. Although the SF is in a conductive state, no ion can flow through the pore as the IG is closed. (B) Membrane depolarization induces a vertical shift in the S4 segment, which also induces a lateral rotation and an upward motion of the S4–S5 linker. (C) S4 repositioning, and the consequent upward motion of the S4–S5 linker, bends the S6 C-terminal half of an adjacent subunit and leads to widening of the IG and an increased hydration of the CC, triggering K+ conduction. Such processes are also accompanied, and possibly facilitated, by the fact that, upon depolarization, the HA and HB helices in the proximal C-terminus, where calmodulin binds in the closed channel configuration, undergo an almost 180° rotation, causing the HA and S6 helices to join in a continuous helix and calmodulin to be released from its attachment site in the S2–S3 linker, as well as by PIP2 repositioning from the S2–S3 linker to the S4–S5 linker. The positions of the ezogabine binding sites (one per subunit) are indicated relative to the overall structure of the channel. (D) A flat ribbon representation of the ezogabine binding site in a Kv7.2 subunit. The illustration shows the ezogabine molecule and the S5 and S6 transmembrane regions from a single Kv7.2 subunit contributing to the binding site. Ionized hydrogen bonds are shown as dashed-yellow lines. The Trp236 residue, which is critical for ezogabine binding, is indicated, together with Leu299 and Ser303 also contributing to drug-channel interactions. Data are from the Protein Data Bank (7CR2) [56, 60]
Fig. 1 Hypothetical mechanism of activation of Kv7 channels by ezogabine. Only two of the four subunits forming the functional channel are shown for simplicity. (A) Under resting conditions, the S4 segment of the voltage-sensing domain (VSD) is positioned toward the intracellular side of the membrane. This configuration is stabilized by calmodulin bridging the core region at the S2–S3 linker [where phosphatidylinositol-4,5-biphosphate (PIP2) also binds] and the C-terminus at two α-helical regions denominated HA and HB. The inner pore gate (IG) is closed, the central cavity (CC) above the IG and below the selectivity filter (SF), is narrow. Although the SF is in a conductive state, no ion can flow through the pore as the IG is closed. (B) Membrane depolarization induces a vertical shift in the S4 segment, which also induces a lateral rotation and an upward motion of the S4–S5 linker. (C) S4 repositioning, and the consequent upward motion of the S4–S5 linker, bends the S6 C-terminal half of an adjacent subunit and leads to widening of the IG and an increased hydration of the CC, triggering K+ conduction. Such processes are also accompanied, and possibly facilitated, by the fact that, upon depolarization, the HA and HB helices in the proximal C-terminus, where calmodulin binds in the closed channel configuration, undergo an almost 180° rotation, causing the HA and S6 helices to join in a continuous helix and calmodulin to be released from its attachment site in the S2–S3 linker, as well as by PIP2 repositioning from the S2–S3 linker to the S4–S5 linker. The positions of the ezogabine binding sites (one per subunit) are indicated relative to the overall structure of the channel. (D) A flat ribbon representation of the ezogabine binding site in a Kv7.2 subunit. The illustration shows the ezogabine molecule and the S5 and S6 transmembrane regions from a single Kv7.2 subunit contributing to the binding site. Ionized hydrogen bonds are shown as dashed-yellow lines. The Trp236 residue, which is critical for ezogabine binding, is indicated, together with Leu299 and Ser303 also contributing to drug-channel interactions. Data are from the Protein Data Bank (7CR2) [56, 60]CC BY-NC · PubMed Central
Fig. 2 Chemical structure of ezogabine
Fig. 2 Chemical structure of ezogabineCC BY-NC · PubMed Central
Fig. 3 Median percent reduction from baseline in focal seizure frequency in patients included in randomized double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine (EZG) in focal epilepsy. Based on data from Porter et al. [111], Brodie et al. [112], and French et al. [113]
Fig. 3 Median percent reduction from baseline in focal seizure frequency in patients included in randomized double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine (EZG) in focal epilepsy. Based on data from Porter et al. [111], Brodie et al. [112], and French et al. [113]CC BY-NC · PubMed Central
Fig. 4 Responder rates (percent of patients with ≥ 50% reduction in focal seizure frequency from baseline) in patients included in randomized, double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine in focal epilepsy. For the study by Porter et al. [111] responder rate was calculated over the entire double-blind treatment period (titration plus maintenance), whereas for the studies by Brodie et al. [112] and French et al. [113] the responder rates shown in the figure were calculated over the maintenance dose period only
Fig. 4 Responder rates (percent of patients with ≥ 50% reduction in focal seizure frequency from baseline) in patients included in randomized, double-blind, placebo-controlled, adjunctive-therapy trials of ezogabine in focal epilepsy. For the study by Porter et al. [111] responder rate was calculated over the entire double-blind treatment period (titration plus maintenance), whereas for the studies by Brodie et al. [112] and French et al. [113] the responder rates shown in the figure were calculated over the maintenance dose period onlyCC BY-NC · PubMed Central
Fig. 5 Chemical structure of azetukalner
Fig. 5 Chemical structure of azetukalnerCC BY-NC · PubMed Central
Fig. 6 Median percent reduction from baseline in focal seizure frequency (left panel) and responder rates (percent of participants with ≥ 50% reduction in focal seizure frequency from baseline, right panel) in patients included in the phase 2b randomized, double-blind, placebo-controlled, adjunctive-therapy trial of azetukalner (AZE) in focal epilepsy. Based on data from French et al. [146]
Fig. 6 Median percent reduction from baseline in focal seizure frequency (left panel) and responder rates (percent of participants with ≥ 50% reduction in focal seizure frequency from baseline, right panel) in patients included in the phase 2b randomized, double-blind, placebo-controlled, adjunctive-therapy trial of azetukalner (AZE) in focal epilepsy. Based on data from French et al. [146]CC BY-NC · PubMed Central
Fig. 7 Chemical structure of pynegabine
Fig. 7 Chemical structure of pynegabineCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. Miceli F, Soldovieri MV, Weckhuysen S, et al. KCNQ2-Related Disorders. 2010 Apr 27 [Updated 2022 May 19]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. https://www.ncbi.nlm.nih.gov/books/NBK32534/.
  2. Pressler R, Taglialatela M, Plouin P, Hassn H. Self-limited (familial) neonatal epilepsy. In: Engel J Jr, Moshé SL, editors, Epilepsy. A Comprehensive Textbook, 3rd edition, Volume 3, Chapter 275, Philadephia: Wolters Kluwer 2024. p. 2817–26
  3. Tandy MD, Cadieux JA, Namdari R. Using modified QbD to develop a novel pediatric formulation of ezogabine. Pharm Technol. 2021;45:44–9. https://www.pharmtech.com/view/using-modified-qbd-to-develop-a-novelpediatric-formulation-of-ezogabine. Accessed 15 Aug 2024.
  4. Goldberg YP. XEN1101, a novel modulator of Kv7.2/3 for the treatment of epilepsy. Slide presentation at the Epilepsy Foundation Pipeline Conference, San Francisco, February 22-23, 2018. https://www.xenon-pharma.com/wp-content/uploads/2018/05/XEN1101_EpilepsyFoundationPresentation_February2018.pdf. Accessed 20 Aug 2024.
  5. French J, Porter R, Perucca E, Brodie M, Rogawski M, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN. Axetukalner (XEN1101), a novel, potent, Kv7 potassium channel opener: Interim data from an ongoing, long-term open-label extension of a phase 2b study (X- TOLE) in adults with focal onset seizures. Poster presented at the 15th European Epilepsy Congress, September 7–11, 2024, Rome, Italy. https://www.xenon-pharma.com/wp-content/uploads/2024/09/EEC24French.pdfy. Accessed 22 Aug 2024. · DOI
  6. Picchione K, Resnick L, Bozik M, Dworetzky S. Characterization of BHV-7000: a novel Kv7.2/7.3 activator for the treatment of seizures. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024. Neurology 102 (suppl 1). https://doi.org/10.1212/WNL.0000000000206250. · DOI
  7. Adis International Ltd. CB 03. AdisInsight, updated 3 October 2024. https://adisinsight.springer.com/drugs/800057520. Accessed 20 Oct 2024.

Cited by

See all 43

Metadata

Authors
Perucca, E., & Taglialatela, M.
Affiliations
  • The University of Melbourne (AU)
  • University of Naples Federico II (IT)
Corresponding author
Perucca, Emilio
Venue
CNS Drugs
Published
2025-01-24
Volume
39
Issue
3
Pages
263-288
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W4406801261
Cited by
43
References
179
Citations by year
2026: 27 · 2025: 16
FWCI
7.62
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
University of Melbourne
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
Kv7 potassium channels, Kv7.2, Kv7.3, KCNQ2, epilepsy, antiepileptic drugs, retigabine, ezogabine, developmental and epileptic encephalopathy, major depressive disorder, generalized tonic-clonic seizures
MeSH terms
Animals, Anticonvulsants, Carbamates, Epilepsy, Humans, Phenylenediamines, KCNQ Potassium Channels, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.